<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Cardiovascular disease: myocardial infarction: non-ST-segment elevation; Myocardial infarction: non-ST-segment elevation; Angina: unstable; Aspirin: angina; Angina: management: aspirin; Angina: management: clopidogrel; Clopidogrel; Angina: management: heparins; Eptifibatide; Tirofiban; Angina: management: aspirin; Aspirin: angina" /><meta name="IX" content="Cardiovascular disease: myocardial infarction: non-ST-segment elevation; Myocardial infarction: non-ST-segment elevation; Angina: unstable; Aspirin: angina; Angina: management: aspirin; Angina: management: clopidogrel; Clopidogrel; Angina: management: heparins; Eptifibatide; Tirofiban; Angina: management: aspirin; Aspirin: angina" /><title>Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI): British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1564-management-of-unstable-angina-and-non-st-segment-elevation-myocardial-infarction-nstemi.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP1564-management-of-unstable-angina-and-non-st-segment-elevation-myocardial-infarction-nstemi.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1564-management-of-unstable-angina-and-non-st-segment-elevation-myocardial-infarction-nstemi.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a> &gt; <a href="PHP1559-stable-angina-acute-coronary-syndromes-and-fibrinolysis.htm">2.10 Stable angina, acute coronary syndromes, and fibrinolysis</a> &gt; <a href="PHP1560-management-of-stable-angina-and-acute-coronary-syndromes.htm">2.10.1 Management of stable angina and acute coronary syndromes</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1563-acute-coronary-syndromes.htm" title="Previous: Acute coronary syndromes">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm" title="Next: Management of ST-segment elevation myocardial infarction (STEMI)">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)</h1><?highlighter on?><div id="pC" class="jN"><p>These conditions are managed similarly; the aims of management are to provide supportive care and pain relief during the acute attack and to prevent further cardiac events and death. For advice on the management of patients with acute ST-segment elevation myocardial infarction (STEMI), see <a title="BNF:topic: Management of ST-segment elevation myocardial infarction" href="PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm">below</a>.</p><div><h2>Initial management</h2><p><strong>Oxygen</strong> (<a title="section: Oxygen" href="PHP2009-oxygen.htm">section 3.6</a>) should be administered if there is evidence of hypoxia, pulmonary oedema, or continuing myocardial ischaemia; hyperoxia should be avoided and particular care is required in patients with chronic obstructive airways disease.</p><p><strong>Nitrates</strong> (<a title="sub-section: Nitrates" href="PHP1256-nitrates.htm">section 2.6.1</a>) are used to relieve ischaemic pain. If sublingual glyceryl trinitrate is not effective, intravenous or buccal glyceryl trinitrate or intravenous isosorbide dinitrate is given. If pain continues, <strong>diamorphine</strong> or <strong>morphine</strong> (<a title="monograph: DIAMORPHINE HYDROCHLORIDE" href="PHP2699-diamorphine-hydrochloride.htm">section 4.7.2</a>) can be given by slow intravenous injection; an antiemetic such as metoclopramide should also be given (<a title="BNF:monograph: METOCLOPRAMIDE HYDROCHLORIDE" href="PHP2547-metoclopramide-hydrochloride.htm">section 4.6</a>).</p><p><strong>Aspirin</strong> (chewed or dispersed in water) is given for its antiplatelet effect in a dose of 300 mg (<a title="section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>). If aspirin is given before arrival at hospital, a note saying that it has been given should be sent with the patient. <strong>Clopidogrel</strong> in a dose of 300 mg (or 600 mg [unlicensed] if used prior to percutaneous coronary intervention) should also be given (see <a title="section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>). <strong>Prasugrel</strong>, in a dose of 60 mg, is an alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention (see <a title="BNF:target-block: nice prasugrel 2009" href="PHP1519-antiplatelet-drugs.htm#PHP1521">NICE guidance</a>). <strong>Ticagrelor</strong>, in a dose of 180 mg, is also an alternative to clopidogrel (see <a title="BNF:target-block: Ticagrelor NICE guidance" href="PHP1519-antiplatelet-drugs.htm#PHP1522">NICE guidance</a>). Patients should also receive either <strong>unfractionated heparin</strong>, a <strong>low molecular weight heparin</strong>, or <strong>fondaparinux</strong> (<a title="sub-section: Parenteral anticoagulants" href="PHP1441-parenteral-anticoagulants.htm">section 2.8.1</a>).</p><p>Patients without contra-indications should receive <strong>beta-blockers</strong> (<a title="section: Beta-adrenoceptor blocking drugs" href="PHP934-beta-adrenoceptor-blocking-drugs.htm">section 2.4</a>) which should be continued indefinitely. In patients without left ventricular dysfunction and in whom beta-blockers are inappropriate, <strong>diltiazem</strong> or <strong>verapamil</strong> can be given (<a title="sub-section: Calcium-channel blockers" href="PHP1309-calcium-channel-blockers.htm">section 2.6.2</a>).</p><p>The glycoprotein IIb/IIIa inhibitors <strong>eptifibatide</strong> and <strong>tirofiban</strong> (<a title="section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>) can be used (with aspirin and unfractionated heparin) for unstable angina or for NSTEMI in patients at a high risk of either myocardial infarction or death.</p><p>In intermediate- and high-risk patients, abciximab, eptifibatide, or tirofiban can also be used with aspirin and unfractionated heparin in patients undergoing percutaneous coronary intervention, to reduce the immediate risk of vascular occlusion. In intermediate- and high-risk patients in whom early intervention is planned, bivalirudin (<a title="BNF:monograph: BIVALIRUDIN" href="PHP1471-bivalirudin.htm">section 2.8.1</a>) can be considered as an alternative to the combination of a glyocprotein IIb/IIIa inhibitor plus a heparin.</p><p>Revascularisation procedures are often appropriate for patients with unstable angina or NSTEMI; see <a title="BNF:target-block: Antiplatelet drugs in coronary stenting" href="PHP1519-antiplatelet-drugs.htm#PHP1523">section 2.9</a> for the use of antiplatelet drugs in patients undergoing coronary stenting.</p></div><div><h2>Long-term management</h2><p>The need for long-term angina treatment or for coronary angiography should be assessed. Most patients will require standard angina treatment (see management of stable angina, above) to prevent recurrence of symptoms.</p></div> <div id="PHP1565"><h2>Prevention of cardiovascular events</h2><p>Patients with stable angina, unstable angina, or NSTEMI should be given advice and treatments to reduce their cardiovascular risk. The importance of life-style changes, especially stopping smoking, should be emphasised. <strong>Aspirin</strong> should be given indefinitely in a dose of 75 mg daily. Antihypertensive treatment should be initiated if appropriate (see <a title="BNF:section: Hypertension and heart failure" href="PHP1034-hypertension-and-heart-failure.htm">section 2.5</a>), and a <strong>statin</strong> (<a title="BNF:monograph-family: Statins" href="PHP1623-statins.htm">section 2.12</a>) should also be given.</p><p>In patients with stable angina, addition of an <strong>ACE inhibitor</strong> (<a title="BNF:sub-sub-section: Angiotensin-converting enzyme inhibitors" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm">section 2.5.5.1</a>) should be considered for patients with diabetes (and should be continued if indicated for a co-morbidity).</p><p>In patients with unstable angina or NSTEMI, clopidogrel (<a title="BNF:section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>) is given, in combination with aspirin, for up to 12 months—most benefit occurs during the first 3 months. Prasugrel or ticagrelor are alternatives to clopidogrel in certain patients (see <a title="BNF:section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>). An ACE inhibitor should also be given.</p></div> </div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1563-acute-coronary-syndromes.htm">Previous: Acute coronary syndromes</a> | <a class="top" href="PHP1564-management-of-unstable-angina-and-non-st-segment-elevation-myocardial-infarction-nstemi.htm#">Top</a> | <a accesskey="]" href="PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm">Next: Management of ST-segment elevation myocardial infarction (STEMI)</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>